Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)
18 Years
N/A
Both
Lung Cancer
Trial Information
Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)
The investigators also want to:
- To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging
of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible -
follow-up (se Gold Standard 6.1.1)
- To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors
- To compare the expression of GLUT1 with the activity of G6Pase
- To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of
relapse within a year after curative surgery
Inclusion Criteria:
- Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after
initial work up
- Candidate to curative intended surgery after initial work up (usually chest x-ray, CT
of chest/upper abdomen and if needed spirometry).
Exclusion Criteria:
- Former lung cancer
- Contraindications for PET/CT: Pregnancy, recent chemoradiotherapy
- Diabetes mellitus.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Sensitivity, specificity and accuracy
Outcome Description:
To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up
Outcome Time Frame:
After staging or 1 year of follow up
Safety Issue:
No
Principal Investigator
Mie H Vilstrup, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Odense University Hospital
Authority:
Denmark: Ethics Committee
Study ID:
NMA 61 DILUCE
NCT ID:
NCT01539928
Start Date:
March 2012
Completion Date:
March 2015
Related Keywords:
- Lung Cancer
- Dual time PET/CT
- glucose-6-phosphatase
- Lung Neoplasms
Name | Location |
|---|
